<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808414</url>
  </required_header>
  <id_info>
    <org_study_id>Qpex-300</org_study_id>
    <nct_id>NCT04808414</nct_id>
  </id_info>
  <brief_title>SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers</brief_title>
  <acronym>QPX9003</acronym>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability and Pharmacokinetics of Intravenous (IV) QPX9003 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qpex Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Qpex Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The worldwide spread of resistance to antibiotics among gram-negative bacteria, particularly&#xD;
      members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of&#xD;
      hospital acquired infections. In particular, the presence of multi-drug resistant&#xD;
      Acinetobacter baumannii and Pseudomonas aeruginosa in hospitals around the world poses a&#xD;
      considerable threat.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The United States (US) Centers for Disease Control (CDC) have listed multidrug-resistant&#xD;
      (MDR) Acinetobacter and MDR Pseudomonas aeruginosa as serious threats [CDC, 2019]. Consistent&#xD;
      with the global nature of these resistant bacteria, the World Health Organization (WHO) has&#xD;
      designated carbapenem-resistant Acinetobacter baumannii, and carbapenem resistant Pseudomonas&#xD;
      aeruginosa as critical threats [WHO, 2017].&#xD;
&#xD;
      To combat these serious threats Qpex has developed QPX9003, a next generation polymyxin that&#xD;
      is more potent than existing polymyxins against P. aeruginosa and A. baumannii and has&#xD;
      exhibited less nephrotoxicity in preclinical studies.&#xD;
&#xD;
      There remains a significant unmet need for new IV agents to treat gram-negative infections&#xD;
      due to resistant bacteria in hospital settings. Some progress has been made in the successful&#xD;
      development of new agents to address drug-resistant infections, particularly IV agents for&#xD;
      resistant gram-negative bacteria [Talbot et al, 2019]. While some of these agents have&#xD;
      addressed urgent threats like carbapenem-resistant Enterobacteriaceae (CRE), their activity&#xD;
      is largely confined to strains producing serine carbapenemases; none of these agents have&#xD;
      reliable activity against metallo beta-lactamase producing CRE. Moreover, none of these&#xD;
      recently approved agents have activity against carbapenem-resistant Acinetobacter baumannii&#xD;
      [Talbot et al, 2019]. The increasing prevalence of multidrug-resistant gram-negative&#xD;
      bacteria, in particular carbapenemase producing Enterobacteriaceae, A. baumannii, and P.&#xD;
      aeruginosa, has resulted in an increase in the use of polymyxin antibiotics as salvage&#xD;
      therapy [Biswas et al. 2017].&#xD;
&#xD;
      This Phase 1 study will assess the safety, tolerability and pharmacokinetics of single and&#xD;
      multiple IV administered ascending doses (SAD/MAD) of IV QPX9003 in healthy adult subjects.&#xD;
&#xD;
      Qpex is developing IV QPX9003 which is a next generation polymyxin with activity against&#xD;
      multi-drug resistant A. baumannii and P. aeruginosa&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2021</start_date>
  <completion_date type="Anticipated">March 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind, placebo controlled ascending single and multiple dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double-blind, placebo controlled ascending single- and multiple-dose</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment -Emergent Adverse events (AEs) by subject and by cohort (single, multiple and combination dose)</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Number of patients with Treatment-Emergent AEs by treatment arm, severity and relationship to treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with changes from baseline in safety parameters (single, multiple and combination dose)</measure>
    <time_frame>up to 13 days</time_frame>
    <description>Number of patients with changes in safety parameters before and after dosing by subject and treatment arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma Concentration measurements by subject and by cohort (Cmax) (single and combination dose)</measure>
    <time_frame>up to 13 days</time_frame>
    <description>Comparison will be performed between the cohorts for Cmax. Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) between cohorts (single and multiple dose)</measure>
    <time_frame>up to 13 days</time_frame>
    <description>Comparison will be performed between the cohorts for AUC. Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine amount excreted by subject and by cohort (single and combination dose)-PK</measure>
    <time_frame>up to 13 days</time_frame>
    <description>Urine amount excreted will be calculated from urinary excretion data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine % dose excreted by subject and by cohort (single and multiple dose)-PK</measure>
    <time_frame>up to 13 days</time_frame>
    <description>Urine amount of % dose excreted will be calculated from urinary excretion data</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>QPX9003 for IV infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV novel polymyxin antibiotic Single and Multiple IV doses x 7 days via IV infusion q6hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV saline Single and Multiple IV doses x 7 days via IV infusion q6hrs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QPX9003 for IV Infusion</intervention_name>
    <description>antibiotic</description>
    <arm_group_label>QPX9003 for IV infusion</arm_group_label>
    <other_name>novel IV polymyxin antibiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for IV infusion</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo for Infusion</arm_group_label>
    <other_name>IV saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult males and/or females of non-child bearing potential, 18 to 60 years of&#xD;
             age (inclusive).&#xD;
&#xD;
          2. Body mass index (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg&#xD;
             (inclusive).&#xD;
&#xD;
          3. Medically healthy with clinically insignificant screening results (e.g., laboratory&#xD;
             profiles, medical histories, electrocardiograms [ECGs], physical examination) as&#xD;
             assessed by the PI.&#xD;
&#xD;
          4. Voluntarily consent to participate in the study.&#xD;
&#xD;
          5. If male, agree to be sexually abstinent or agree to use a condom when engaging in any&#xD;
             sexual activity from Day -1 check-in to the clinic through 30 days following the last&#xD;
             administration of the study drug, and to not donate sperm during this same period of&#xD;
             time.. If engaging in sexual activity with a female partner of childbearing potential,&#xD;
             an additional method of birth control must be used.&#xD;
&#xD;
             Approved additional methods of birth control include:&#xD;
&#xD;
               1. Intra-uterine device (IUD) in place for at least 3 months prior to Day 1 through&#xD;
                  30 days following the final dosing of the study drug.&#xD;
&#xD;
               2. Barrier method (diaphragm) for at least 14 days prior to Day 1 through 30 days&#xD;
                  following the final dosing of the study drug.&#xD;
&#xD;
               3. Stable hormonal contraceptive for at least 3 months prior to Day 1 through 30&#xD;
                  days following the final dosing of the study drug.&#xD;
&#xD;
               4. Surgical sterilization (vasectomy) at least 6 months prior to Day 1.&#xD;
&#xD;
          6. Females of non-childbearing potential must meet at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               1. postmenopausal (defined as 12 months spontaneous amenorrhea) with a serum FSH&#xD;
                  leve l≥ 40 mIU/mL.&#xD;
&#xD;
               2. have undergone one of the following sterilization procedures documented at least&#xD;
                  6 months prior to Day 1:&#xD;
&#xD;
                    -  Bilateral tubal ligation&#xD;
&#xD;
                    -  Hysterectomy&#xD;
&#xD;
                    -  Hysterectomy with unilateral or bilateral oophorectomy&#xD;
&#xD;
                    -  Bilateral oophorectomy&#xD;
&#xD;
               3. Females who practice true abstinence or are in same sex relationships where there&#xD;
                  is no possibility of conception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,&#xD;
             or psychiatric disease.&#xD;
&#xD;
          2. Positive urine drug screen or alcohol breath test at screening or check-in (Day -1).&#xD;
&#xD;
          3. Positive testing for HIV, hepatitis B or C&#xD;
&#xD;
          4. History or presence of alcoholism or drug abuse within last 2 years&#xD;
&#xD;
          5. Use of more than 5 packs/week of tobacco/nicotine-containing product within last 6&#xD;
             months prior dosing.&#xD;
&#xD;
          6. Use of any prescription medication (with the exception of hormonal contraceptives or&#xD;
             hormone replacement therapy for females) within 14 days prior to dosing.&#xD;
&#xD;
          7. Use of any over-the-counter (OTC) medication, including herbal products, probiotics&#xD;
             and vitamins, within the 7 days prior to dosing.&#xD;
&#xD;
          8. Use of antacids, H2 receptor blockers or proton pump inhibitors 7 days prior to&#xD;
             dosing.&#xD;
&#xD;
          9. History of any hypersensitivity reaction or anaphylaxis to any medication, including&#xD;
             polymyxin antibiotics.&#xD;
&#xD;
         10. Participation in another investigational clinical trial within 30 days prior to Day 1&#xD;
             or within 5 half-lives of the previous investigational drug, whichever is longer.&#xD;
&#xD;
         11. Females who are pregnant or lactating.&#xD;
&#xD;
         12. QTcF interval &gt;450 msec for males and &gt;470 msec for females, or history of prolonged&#xD;
             QT syndrome at screening or check-in.&#xD;
&#xD;
         13. Calculated creatinine clearance less than 80 mL/min (Cockcroft-Gault method) at&#xD;
             screening or check-in.&#xD;
&#xD;
         14. Subjects who have any clinically significant abnormalities on laboratory values: White&#xD;
             blood cell count &lt; 3,000/mm3, hemoglobin &lt; 11g/dL or Absolute neutrophil count &lt;&#xD;
             1,200/mm3 or platelet count &lt; 120,000/mm3.&#xD;
&#xD;
         15. Liver function abnormalities defined by an elevation in bilirubin, Aspartate&#xD;
             Aminotransferase (AST) or Alanine Aminotransferase (ALT) 1.5 x Upper Limit of Normal&#xD;
             (ULN) of the normal range for subjects based on age and sex.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffery S Loutit, MBChB</last_name>
    <role>Study Director</role>
    <affiliation>Qpex Biopharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth E Morgan</last_name>
    <phone>858-500-8388</phone>
    <email>lmorgan@qpexbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarabeth Alonso</last_name>
      <phone>714-252-0700</phone>
      <phone_ext>1951</phone_ext>
      <email>sarabeth.alonso@wcct.-com</email>
    </contact>
    <investigator>
      <last_name>Helen Paguntalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>polymyxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Polymyxins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

